Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.

by: Iola Bonggay

The United States Food and Drug Administration, otherwise referred to as the USFDA, an agency operating within the United States Department of Health and Human Services that is generally responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, veterinary products, and cosmetics.

The USFA has recently formed a collaboration with the National Institutes of Health to establish the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.

The primary goal of the program is to develop computational fluid dynamics (CFD) model of orally inhaled drug products that can account for drug product characteristics and physiological parameters on total and regional deposition in the lungs.

This is all in conjunction with the USFDA's objective of developing a CFD model that will be capable of of predicting highly localized deposition of pharmaceutically relevant polydisperse aerosols from metered dose inhalers (MDIs) and dry powder inhalers (DPIs).

In addition, the results that will be derived from this study will then be utilized to create a linked CFD-compartment model that can predict the effects of lung deposition on safety (systemic exposure) and efficacy (local delivery) for locally acting orally inhaled drugs.

  (continued...)

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
  Page 2

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Excellence in Hemoglobinopathies Research Award Program
The National Institutes of Health has formed a collaboration with the National Heart, Lung, and Blood Institute (NHLBI) in an effort to establish the Excellence in Hemoglobinopathies Research Award Program wherein both agencies have agreed to financially support the creation of studies that could potentially improve high-impact multi-disciplinary basic and translational research studies in the hemoglobinopathies.

---

Critical Congenital Heart Disease Newborn Screening Demonstration Program
The Health Resources and Services Administration has recently constituted the Critical Congenital Heart Disease (CCHD) Newborn Screening Demonstration Program in order to support and encourage the development, dissemination, and validation of screening protocols and newborn screening infrastructure for point of care screenings that are specific to Critical Congenital Heart Diseases.

---

Health Resources and Services Administration's Licensure Portability Grant Program
The Health Resources and Services Administration has constituted the Licensure Portability Grant Program (LPGP) wherein they aim to improve the experience of State licensing boards that have manifested a credible record in implementing cross-border activities in order to help overcome licensure barriers in the provision of telemedicine services across various States.

---

Pilot Studies of Innovative Treatments in Mental Disorders Project
The National Institutes of Health has recently collaborated with the National Institutes of Mental Health (NIMH) to establish the Pilot Studies of Innovative Treatments in Mental Disorders Program.

---